{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-030033","form_type":"8-K","ticker":"MIRA","cik":"0001904286","company_name":"MIRA PHARMACEUTICALS, INC.","filed_at":"2026-06-25T12:00:40+00:00","discovered_at":"2026-06-25T12:05:00.304963+00:00","generated_at":"2026-06-25T12:05:52.394941+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"MIRA Pharma reports preclinical data showing Mira-55 differentiated from THC, anxiolytic effect","bullets":["Mira-55 did not produce THC-like locomotor suppression or catalepsy in standard preclinical assays.","Modest body temperature reduction from Mira-55 was not reversed by CB1 antagonist rimonabant, indicating distinct mechanism.","Mira-55 demonstrated anxiolytic activity, in contrast to anxiogenic activity of rimonabant; THC showed no anxiolysis.","Data builds on March 2026 results; company advancing Mira-55 toward IND for chronic inflammatory pain.","No psychoactivity or CNS side effects observed; candidate designed to avoid THC liabilities."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-030033","json":"https://secwatch.observer/filing/0001493152-26-030033.json","markdown":"https://secwatch.observer/filing/0001493152-26-030033.md","text":"https://secwatch.observer/filing/0001493152-26-030033.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1904286/000149315226030033/0001493152-26-030033-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1904286/000149315226030033/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T12:05:52.394941+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}